Trials / Completed
CompletedNCT01621256
Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss
Double-blind, Randomized, Placebo-controlled Study on Efficacy, Safety and Tolerability of Ancrod in Patients With Sudden Sensorineural Hearing Loss (SSHL)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Nordmark Arzneimittel GmbH & Co. KG · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ancrod is effective and safe in the treatment of sudden sensorineural hearing loss (SSHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ancrod | Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections |
| DRUG | Saline solution | Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2018-09-18
- Completion
- 2018-10-30
- First posted
- 2012-06-18
- Last updated
- 2018-12-21
Locations
7 sites across 2 countries: Czechia, Germany
Source: ClinicalTrials.gov record NCT01621256. Inclusion in this directory is not an endorsement.